Predict your next investment

HEALTHCARE | Drug Development
impactbiomedicines.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$112.5M

Valuation

$0000 

About Impact Biomedicines

Impact Biomedicines is developing treatments for patients with complex cancers. The company's pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis and polycythemia vera.

Impact Biomedicines Headquarter Location

12526 High Bluff Drive Suite 260

San Diego, California, 92130,

United States

858-221-0950

Latest Impact Biomedicines News

Drugs Get a Second Chance

Aug 25, 2019

John Hood couldn’t understand why pharmaceutical Sanofi shelved a promising cancer program. So, he took action. Hood founded Impact Biomedicines in 2016 to resurrect fedratinib, a drug he co-invented years earlier to treat a deadly bone marrow cancer called myelofibrosis. His effort proved worthwhile: On Aug. 16, the U.S. Food and Drug Administration approved fedratinib. Celgene — which in early 2018 bought Impact BioMedicines for up to $7 billion — said the drug is the first new treatment for myelofibrosis patients in a decade. “It’s a huge win for patients and a great win for San Diego,” said Hood, who was the CEO of Impact Biomedicines, which was founded locally. Second Chances Impact Biomedicines isn’t alone. Other biotechs are banking on companies’ scrapped or stalled ideas, including Kura Oncology and Mirum Pharmaceuticals. After finding what were thought to be failures, these companies navigated tricky licensing negotiations and convinced skeptical investors to give programs another go. Hood believed in fedratinib so much that he put down a quarter million dollars of his money as a down payment to get the drug back, on the bet he could secure $5 million in investor cash within 120 days. He co-invented the medicine while working at TargeGen, a San Diego company that French drugmaker Sanofi acquired in 2010. But several years later Sanofi shelved fedratinib, by then a late-stage program. The pharmaceutical made the decision after the FDA slapped a clinical hold on the drug after a few patients reportedly developed the neurological condition Wernicke’s encephalopathy. Another Look at the Data With fedratinib no longer available, relapsing patients contacted Hood. He took another look at the patient data. “I thought the reasoning behind the clinical trial stoppage was spurious and incorrect,” Hood said. “I know patients suffered because of it.” Hood said a “bad confluence of events” explain Sanofi’s decision. He cited the pharmaceutical coming off clinical trial failures and fedratinib competition. “This thing had two strikes on it before it ever stepped up to the plate,” he said. Another major advocate of restarting was Catriona Jamieson, a researcher and physician at UC San Diego Moores Cancer Center who treated patients with the drug. By 2016, newly formed Impact Biomedicines advanced the drug and showed it did not increase the risk of Wernicke’s encephalopathy. The FDA hold was lifted, sparking the Celgene deal. New Jersey-based Celgene paid $1.1 billion upfront in cash. With the FDA approval Impact Biomedicines received an undisclosed payment. Factoring in royalties, the deal is worth up to $7 billion.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Impact Biomedicines

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Impact Biomedicines in 1 CB Insights research brief, most recently on Jan 23, 2019.

Expert Collections containing Impact Biomedicines

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Impact Biomedicines is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Impact Biomedicines Patents

Impact Biomedicines has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Myeloid neoplasia
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/6/2013

8/27/2019

Rare diseases, Clusters of differentiation, Transcription factors, Myeloid neoplasia, Syndromes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/6/2013

00/00/0000

00/00/0000

Grant Date

8/27/2019

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Rare diseases, Clusters of differentiation, Transcription factors, Myeloid neoplasia, Syndromes

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.